Shanghai - Delayed Quote CNY

Wuhan Keqian Biology Co.,Ltd (688526.SS)

Compare
12.80
-0.25
(-1.92%)
As of 2:21:00 PM GMT+8. Market Open.
Loading Chart for 688526.SS
DELL
  • Previous Close 13.05
  • Open 12.97
  • Bid 12.78 x --
  • Ask 12.79 x --
  • Day's Range 12.76 - 13.10
  • 52 Week Range 11.00 - 20.15
  • Volume 2,748,288
  • Avg. Volume 2,696,282
  • Market Cap (intraday) 5.966B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 20.00
  • EPS (TTM) 0.64
  • Earnings Date --
  • Forward Dividend & Yield 0.43 (3.30%)
  • Ex-Dividend Date May 22, 2024
  • 1y Target Est --

Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.

www.kqbio.com

923

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688526.SS

View More

Performance Overview: 688526.SS

Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

688526.SS
12.93%
SSE Composite Index
5.22%

1-Year Return

688526.SS
31.64%
SSE Composite Index
12.06%

3-Year Return

688526.SS
54.16%
SSE Composite Index
8.29%

5-Year Return

688526.SS
56.61%
SSE Composite Index
3.95%

Compare To: 688526.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688526.SS

View More

Valuation Measures

As of 1/14/2025
  • Market Cap

    6.08B

  • Enterprise Value

    5.08B

  • Trailing P/E

    20.39

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.75

  • Price/Book (mrq)

    1.58

  • Enterprise Value/Revenue

    5.63

  • Enterprise Value/EBITDA

    14.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    33.16%

  • Return on Assets (ttm)

    3.30%

  • Return on Equity (ttm)

    7.83%

  • Revenue (ttm)

    902.14M

  • Net Income Avi to Common (ttm)

    299.11M

  • Diluted EPS (ttm)

    0.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.07B

  • Total Debt/Equity (mrq)

    1.65%

  • Levered Free Cash Flow (ttm)

    119.37M

Research Analysis: 688526.SS

View More

People Also Watch